Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global diabetic foot ulcer therapeutics market was evaluated at US$ 4,901.1 million, in terms of value, in 2018 and is estimated to reach US$ 12,021.8 million by the end of 2027.
A diabetic foot ulcer patient loses the ability to feel pain. Redness and swelling of the foot are some common symptoms of the disease. There are various topical therapeutics available for the treatment of diabetic foot ulcers, such as polyhexamethylene biguanide gel or solutions, dressings containing silver, iodine, and medical-grade honey in ointments or gels.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1357
Developments in regenerative technology are projected to bolster the global diabetic foot ulcer therapeutics market growth over the forecast period. For instance, in July 2019, AVITA Medical announced positive results for a study that assessed its RECELL Autologous Cell Harvesting Device for the treatment of diabetic foot ulcers. Burgeoning incidence of obesity offers lucrative growth prospects for the key players in this market. According to the MedAlertHelp.org, over 1.9 billion adults were reported as overweight worldwide. However, a major constraining factor for the global market development is the availability of alternatives, such as diabetic shoes and natural remedies.
The advanced wound dressings segment in the global diabetic foot ulcer therapeutics market is predicted to garner up to US$ 3,583.0 million by 2027 at a CAGR of 7.3% over the forecast timeline. Increasing product launches is expected to support growth of the segment over the forecast period. For instance, KCI, an Acelity Company recently expanded its advanced wound dressings (AWD) presence in South Africa with the launch of Kerracontact Ag Dressing, Kerrafoam Gentle Border Dressing, and Kerramax Care Dressing in July 2019.
Browse Press Release: https://bit.ly/33dchJu
The neuropathic ulcers segment dominated the global diabetic foot ulcer therapeutics market in 2018, accounting for a 50.5% market. Surging prevalence of diabetes is a major factor driving growth of the segment. As According to WHO, The number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. According to a report published by Center for Disease Control and Prevention in 2017, over 100 million of the adults in the U.S. are suffering from prediabetes or diabetes
Among end users, the hospitals segment emerged as the leading segment in the global diabetic foot ulcer therapeutics market in 2018, accounting for a 37.2% market share. Increasing hospitalizations for treatment of diabetes foot ulcers is expected to support growth of the segment. As per Diabetes Australia, every year there are 10,000 hospital admissions in Australia for diabetes-related foot ulcers.
The market in emerging economies is driven by rapid growth in medical tourism. For instance, according to India Brand Equity Foundation’s January 2019 release, the estimated Foreign Tourist Arrivals (FTAs) in India on medical purpose during the years 2015, 2016, and 2017 were 2,33,918, 4,27,014, and 4,95,056 respectively.
Epidermal growth factor is effective in the treatment of diabetic foot ulcers. For instance, in July 2019, researchers at University of Debrecen (Hungary) and Thach University of Medicine (Vietnam) reported positive results for the use of recombinant human epidermal growth factor in the treatment of diabetic foot ulcers.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1357
The notable companies operating in the global diabetic foot ulcer therapeutics market include B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., 3M, and Acelity L.P. Inc.
In December 2019, Orpyx Medical Technologies Inc. launched Orpyx SI Sensory Insoles with Remote Patient Monitoring for the prevention of diabetic foot ulcers and neuropathy-related ulcers.
In November 2019, Pergamum AB, a subsidiary of Promore Pharma AB, a Sweden –based biopharmaceutical company, received a patent in the US for the pharmaceutical formulation of the product candidate PXL01 used for the treatment of diabetic foot ulcers.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1357
- By Product
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- By Ulcer Type
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-Ischemic Ulcers
- By End-User
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- By Region
- North America
- Latin America
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027